Weight Management and Healthcare Utilization among Adults with Overweight and Obesity in Germany: A Representative Survey of General Practitioner Consultations and Digital and Pharmacological Treatment Options Authors: Laura Kudlek, Hannah Z. Hennig, Hannah Haumann, Falko F. Sniehotta Published: 2026 ABSTRACT AbstractIntroductionObesity prevalence is high, requiring effective and scalable treatment options. German guidelines recommend referral to multimodal treatment programmes. However, reimbursement by statutory health insurance remains fragmented. Little is known about how people with overweight and obesity engage with available support in Germany.MethodsAn online survey was administered to a representative sample of adults living with overweight or obesity in Germany. Participants reported awareness, use, interest, and perceived barriers regarding uptake of (a) primary care consultations, (b) behavioural programmes, and (c) pharmacotherapy for obesity.ResultsA total of 2,065 respondents (46.5% women; 53.3% with overweight; 46.7% with obesity) were included. Most had experience with weight management (85.5%), but approaches were predominantly self-directed (75.1%). Engagement with professional obesity care was limited (conversations with general practitioners: 43.1%; participation in structured behavioural weight management programme: 7.8%; use of pharmacotherapy: 6.2%). Awareness and interest varied across treatment modalities, with particularly low awareness (19.6%) but high interest (39.1%) in behavioural programmes. Common barriers included lack of awareness, concerns about long-term effectiveness and side effects, and perception that support was not yet necessary.ConclusionWe identify a substantial evidence-practice gap in German obesity care, characterized by low reported use of professional support despite widespread weight management attempts. Beyond improving access and availability of services, effective obesity care also requires better communication on the effectiveness of evidence-based treatments, in particular behavioural programmes. Additionally, promoting a long-term, chronic-disease model of obesity and weight management may help align expectations, reduce discontinuation, and support sustained engagement with care. Introduction The prevalence of overweight and obesity has increased globally over the past few decades [1, 2], including in Germany, where about 53% of the population are estimated to live with overweight and 19% with obesity [3, 4]. Since obesity increases the risk of developing various non-communicable conditions, such as diabetes, cardiovascular disease, certain cancers, and other metabolic disorders, it poses a significant risk to public health and contributes to a reduced quality of life and higher mortality rates [5]. While the German government acknowledges the importance of preventing further increases in obesity prevalence, translation of appropriate public health strategies has been limited [6, 7], and rates of overweight and obesity continue to grow [8]. Thus, the implementation of scalable treatment options remains crucial. Meaningful weight loss is achievable through a range of non-surgical interventions, including dietary approaches, behavioural and psychological interventions, and pharmacotherapy [9]. Importantly, recent evidence suggests that such programmes can reduce cardiometabolic risk factors despite weight regain, suggesting health benefits independent of weight loss maintenance [10]. Studies also show that when general practitioners (GPs) actively refer patients to behavioural weight management programmes, rather than providing brief advice alone, this leads to significantly greater weight loss, with benefits lasting up to 5 years after referral [11–14]. These findings highlight the potential for scalability of treatment by embedding evidence-based weight management in primary care [13]. In Germany, national guidelines recommend multimodal programmes that combine nutrition, physical activity, and behaviour change strategies [15]. In practice, however, the availability of such programmes remains limited: regional programmes and nutrition counselling exist, but reimbursement is often decided on a case-by-case basis [16]. Since 2019, GPs have also been able to prescribe Digital Health Applications (“DiGAs”) for obesity, with two approved programmes currently available (Oviva and Zanadio) [16]. However, although they are the only universally reimbursed treatment option, DiGA awareness and uptake among eligible individuals remain low [17], and barriers to their use are unclear. The same applies to pharmacotherapy, which is not reimbursed in Germany, and for which little is known about public awareness, demand or concerns among those living with overweight and obesity. These gaps in knowledge limit insights into how treatment delivery could be improved to accommodate high obesity prevalence rates. In this study, we conducted a representative online survey of adults with a Body Mass Index (BMI) ≥25 kg/m2 to describe how they engage with available obesity care in Germany. We assessed awareness, uptake, and barriers to professional support, including GP consultations, structured multimodal programmes and DiGAs, and pharmacological treatment. By mapping awareness and engagement with available treatment options, our findings may inform future strategies to improve equitable access to obesity care and guide health policy in Germany. Methods Participants and Recruitment Recruitment and data collection were managed by the ISO 20252:2019 certified “Arbeitskreis Deutscher Markt- und Sozialforschungsinstitute e.V.” member “Gesellschaft für Innovative Marktforschung” (engl. Society for Innovative Market Research; GIM). Participants aged ≥18 years, proficient in German language and with access to the Internet were recruited from two established offline-recruitment panels (PAYBACK and GIMPulse) and invited to participate via e-mail and personalized links. The sampling strategy aimed to approximate representativeness of the German adult population across the dimensions of gender, age, education, and federal state. A quota-based sampling approach was applied using population benchmarks derived from the MA-Audio study [18]. As sufficiently precise post-COVID-19 pandemic prevalence numbers for overweight and obesity across sociodemographic subgroups (gender, age, education, and federal state) are not available for Germany, the quotas were applied to the gross sample (i.e., all participants, irrespective of BMI), and people from different sociodemographic subgroups were invited iteratively until the quota targets were met. The final analytic sample, containing only participants with a self-reported BMI of ≥25 kg/m2, was subsequently derived from this initial quota-based gross sample. Ethical approval was obtained on 29 April 2025 from the Ethics Committee of the Medical Faculty Mannheim of the University of Heidelberg (Rec. 2025-517-AF 5). All participants provided informed e-consent prior to completing the survey. The survey was conducted as Computer Assisted Web Interviews (CAWI) between 28 April 2025 and 14 July 2025. Materials The survey was developed to obtain an overview of weight management behaviour in Germany (online suppl. Section 1.0; for all online suppl. material, see https://doi.org/10.1159/000552226). It consisted of a combination of standard demographic questions, validated questionnaires, and in-house designed questions. Socio-demographic questions included items on age, education, immigration, and household size and income and were designed in accordance with the recommendations of the demographic standards and the Robert Koch-Institute [19, 20]. Education was classified according to the international standard classification of education (ISCED) [21]. Health status was assessed using the self-rated health scale [22–24], the quality of life scale (L-1) [25, 26], and a set of items on common comorbidities of obesity. Questions on weight management attitudes and behaviour were developed in-house and were partly guided by findings from previous literature [27–32]. Items referring to specific treatment options were informed by the national treatment guidelines published by the German association for the study of obesity (“S3 Leitline zur Prävention und Therapie der Adipositas”) [15] and their patient version [33]. The survey was piloted with the first 100 participants to ensure feasibility and comprehension. Data Analysis An analysis plan was preregistered on the Open Science Framework (https://doi.org/10.17605/OSF.IO/KAWB9) [34]. Data were processed using R statistical software (v4.5.1) [35] using the dplyr package [36] and examined through visual inspection of histograms. Plausibility checks included verifying that key variables (e.g., age, height, weight) and survey completion times fell within expected ranges, as well as checking for duplicate submissions and sufficient variation in Likert-scale responses. Missing data were handled using pairwise deletion. Fisher’s exact tests were conducted to examine whether the proportions of participants who had used or were interested in using different weight management approaches (i.e., GP support, behavioural weight loss programmes, and medication) differed between BMI groups (overweight: ≥25 to <30 kg/m2; obesity ≥30 kg/m2). Results Sample Characteristics Overall, 11,368 people were invited. Of 3,478 gross-sample participants, 2,138 met the BMI criterion and a final set of 2,065 complete questionnaires were obtained for the final analytic sample. Participants had a median age of 55 (IQR 40–66), a median BMI of 29.46 (IQR 27.07–33.21) and 46.5% were women. Overall, 13.5% of participants reported a migration background. Education levels were mostly medium (61.7%), followed by high levels (31.1%). The median adjusted net monthly income, weighing household size and age of household members, was EUR 2,000 (IQR 1,400–2,666). Most participants had public health insurance (87.2%) and 11.2% were privately insured (Table 1). Table 1.Sample characteristics​Full sample (N = 2,065)Age (median [min–max])55 [18–91]Gender Male53.1% Female46.5% Other0.4%Education Lowa7.2% Mediumb61.7% Highc31.1% Unknown or still in education0.5%Adjusted income (median [IQR])d2,000 (1,400–2,666)BMI (median [min–max])29.46 [25–70.25] BMI 25–3053.3% BMI 30–3529.4% BMI 35–4010.7% BMI ≥406.6%Migration background13.5%Health insurance Public87.2% Private11.2% Other1.5% aReflecting International Standard Classification of Education (ISCED) levels 1–2. bReflecting International Standard Classification of Education (ISCED) levels 3–4. cReflecting International Standard Classification of Education (ISCED) levels 5–8. dRepresents the net monthly household income weighted by household size and age of members (first adult 1, additional ≥14 years = 0.5, children <14 years = 0.3). Sample characteristics aReflecting International Standard Classification of Education (ISCED) levels 1–2. bReflecting International Standard Classification of Education (ISCED) levels 3–4. cReflecting International Standard Classification of Education (ISCED) levels 5–8. dRepresents the net monthly household income weighted by household size and age of members (first adult 1, additional ≥14 years = 0.5, children <14 years = 0.3). Overall, 67.9% of participants self-reported at least one physical comorbidity (Table 2), most commonly including hypertension (37.2%), arthrosis (21.0%), mobility problems (18.6%), chronic pain (16.8%), and type two diabetes (14.5%) (online suppl. Table 3-1). Diagnosed mental health comorbidities were self-reported by 24.0% of participants (Table 2), with the most commonly reported conditions being depression (18.9%), anxiety disorders (8.9%), and post-traumatic stress disorder (4.0%) (online suppl. Table 3-2). Overall, 14.5% of participants reported to be in insurance reimbursed psychological treatment for a mental health condition (Table 2). Participants rated their overall health as very good (4.0%), good (44.7%), mediocre (40.3%), bad (9.8%), and very bad (1.2%). The mean quality of life was rated as 7.43 (SD 2.21) on a scale from 1 to 10, with higher scores indicating greater quality of life (SD 2.21). Table 2.Comorbidities, weight management attitudes, and past weight management attempts​BMI ≥25 to <30 (N = 1,101)BMI ≥30 (N = 964)Full sample (N = 2,065)One or more physiological comorbidities (%)684 (62.1)719 (74.6)1,403 (67.9)One or more mental health comorbidities (%)217 (19.7)279 (28.9)496 (24)In reimbursed treatment for a psychological condition (%)126 (11.4)174 (18)300 (14.5)Previous or current weight loss attempt (%)899 (81.7)873 (90.6)1,772 (85.8)Agreement obesity being a chronic disease (mean [SD])a2.72 (0.71)2.94 (0.73)2.82 (0.73)Rated importance of weight management (mean [SD])b3.2 (0.52)3.14 (0.53)3.17 (0.52) aReported on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). bReported on a Likert scale from 1 (not at all important) to 4 (very important). Comorbidities, weight management attitudes, and past weight management attempts aReported on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). bReported on a Likert scale from 1 (not at all important) to 4 (very important). Reasons for Weight Management, Timeframe, Approaches, and Experience Around 86.0% of participants reported to have tried to regulate their weight, and they rated the importance of weight management as 3.17 (SD 0.52) on a scale from 1 to 4 (Table 2). For participants reporting experience with weight management, the most common reasons for wanting to regulate bodyweight were to improve general health (78.0%), to improve mobility (65.2%), to improve appearance (53.4%), and to improve self-esteem (49.8%) (online suppl. Table 4-1). Most participants reported to having started weight management attempts either over the past year (39.7%) or over the past 5 years (33.2%). Overall, 16.0% reported having attempted to lose weight for more than 5 years, and 11.1% indicated a timeframe reaching back to childhood (online suppl. Table 4-2). Weight management attempts were mostly self-directed (75.1%). Only 15.7% of participants indicated to have sought support from doctors, 11.6% from other medical staff, and 18.4% from commercial providers (online suppl. Table 4-3). Most participants reported to have either partially (37.0%) or fully (33.9%) regained lost weight, with 15.6% indicating not to have lost any weight, and only 18.2% indicating to have maintained weight loss (online suppl. Table 4-4). Overall, 1.6% of participants reported they underwent bariatric surgery. General Practitioner Support for Weight Management Overall, 62.3% of participants believed that talking to a GP about weight management would be helpful or very helpful (Fig. 1). In practice, 43.1% reported having had such conversations with their GPs, with 28.3% initiated by the participants and 14.8% by the GPs. A further 14.7% of participants who had not yet talked to their GP about weight management would like to do so, whereas 42.2% indicated they would not like to discuss weight management with their GP (Fig. 2). Of those that reported past GP conversations, 54.3% rated their experience as helpful or very helpful (Fig. 3). Beliefs about helpfulness/effectiveness of approaches to weight management. Conversation with GP was rated on helpfulness; all other items were rated on effectiveness. Use and interest in different approaches to weight management. Experienced helpfulness/effectiveness of approaches to weight management. Conversation with GP was rated on helpfulness; all other items were rated on effectiveness. Of those that had talked to their GP about weight management (N = 890), most people reported to either have received general tips on diet and exercise without specific action (40.1%), no specific recommendation (14.8%), a warning without further recommendations or action (10.1%), or a recommendation to initiate a self-directed weight loss attempt (9.3%). Specific recommendations and referrals were less common. These included recommending self-paid private nutrition counselling (7.5%), consulting on obesity medications (7.5%), providing a certificate allowing patients to obtain reimbursed nutrition counselling (5.4%), reimbursed DiGAs (4.5%), referral to an obesity specialist (4.5%), referral to a specific nutritionist (4.3%), consulting on bariatric surgery (4.0%), recommending repeated visits to primary care (4.0%), recommending self-paid use of a commercial programme (3.0%), and recommending psychological treatment (2.4%) (Fig. 4). Time to treatment upon referral is presented in online supplementary Figure 6-2. The median time to surgery from initial GP consultation was 34.8 (IQR 22.8–52.1) weeks, 8.7 (IQR 3.7–16.2) weeks to treatment by an obesity specialist, 6 (IQR 3.5–10.8) weeks to treatment by a psychologist, 3 (IQR 2.0–12.2) weeks to treatment by a nutritionist, 6 (IQR 1.4–26.0) weeks to medication, and 2 (IQR 1.0–6.0) weeks to DiGA treatment. GP consultation outcomes. Includes only participants reporting a previous conversation with their GP about weight management. Multiple answer options possible for answer options other than general tips, warning, and nothing, whereby warning and general tips could be selected together. Percentages indicate the proportion of participants within each BMI group who self-reported reported the respective outcome (BMI ≥25: total, N = 890; BMI ≥30: total, N = 560). Of those that had not yet talked to their GP about weight management but would like to do so (N = 304), people mainly wished for general tips (51.6%), a medication consult (23.0%), and nutrition referrals (22.4% private nutrition, 22.0% referral, 20.1% certificate for reimbursed nutrition) (online suppl. Fig. 6-1). When asked about reasons for not having initiated a GP conversation yet, most participants indicated they felt they did not need help with weight management urgently enough (40.5%), they were unsure if their GP could help (28.9%), felt their GP would not take their weight management seriously enough (19.4%) or felt uncomfortable talking about weight (19.1%) (online suppl. Fig. 6-3). Of those that did not want to talk to their GP about weight management (N = 871), reasons included not feeling they needed help with weight management urgently enough (37.8%), believing the GP is not the right place for weight management support (26.1%), participants not trying to change their weight currently (25.0%), and not thinking the GP could help (22.7%) (online suppl. Fig. 6-5). Participants with obesity (BMI ≥30) were more likely than those with overweight (BMI ≥25 to <30) to report a GP consultation on weight management (OR = 3.24; CI 2.69–3.90; p < 0.001) and to be interested in receiving one (OR = 2.24; CI 1.69–2.95; p < 0.001) (also see online suppl. Fig. 5-1–5-3). Barriers to talking their GP and reasons for not wanting to do so are displayed in online supplementary Figures 6-4 and 6-6. Behavioural Weight Management Programmes and DiGAs Overall, 58.4% of participants believed behavioural weight management programmes in general to be effective or very effective for weight management (Fig. 1). Only 19.6% of participants indicated to be aware of DiGAs as medically certified and reimbursed treatment options. After provided with a definition, 54.7% of participants reported to believe they may be effective or very effective for weight management (Fig. 1). When asked about specific programmes listed in the German treatment guidelines and its patient-centred version (S3 Leitline zur Prävention und Therapie der Adipositas) [15, 33], participants were most familiar with Weight Watchers (78.9%), Oviva (19.0%), and the partially reimbursed regional programme “Abnehmen mit Genuss” that is promoted by the health insurance company AOK (17.7%). Overall, 16.5% indicated not to be aware of any of the listed programmes (online suppl. Fig. 5-1). Participants were most commonly aware of programmes through advertisements (31.7%), hearing about programmes from friends and family (25.5%), or through their own research (20.5%) (online suppl. Table 7-1). Only 7.8% of participants had previously participated in either a behavioural weight management programme or DiGA, while a further 39.1% indicated they would want to do so. About half of participants were not interested in behavioural weight management programmes or DiGAs (Fig. 2). Of those that had participated in a behavioural weight management programme or DiGA (N = 161), 9.9% rated it as very effective and 41.6% as effective; however, 48.5% did not find it helpful or not at all helpful (Fig. 3). Again, Weight Watchers (37.3%) and Oviva (25.5%) were amongst the most commonly used programmes (online suppl. Fig. 7-2). Of those that had not yet participated in a behavioural weight management programme or DiGA but would like to do so (N = 808), most people indicated not knowing about these programmes before as reason (56.6%). Other barriers included being unsure what programme would be a good fit (19.2%), doubting the long-term effectiveness of programmes (16.7%), difficulties organizing participation in such a programme due to travel or time commitments (13.6%), doubting its effectiveness for weight loss and doubting programmes would represent participants’ best interests (12.3%) (online suppl. Fig. 7-3). Of those that did not want to participate in a behavioural weight management programme or DiGA (N = 1,096), most common reasons included not believing the programme would be effective long term (28.4%), not actively trying to manage weight at the time (24.1%), not feeling they needed help with weight management urgently enough yet (22.8%), not believing in the effectiveness of these programmes for weight loss (21.6%), not believing the programmes would represent their best interests (16.9%), and believing the programme would be the wrong approach for them (13.0%) (online suppl. Fig. 7-5). Participants with obesity (BMI ≥30) were more likely than those with overweight (BMI ≥25 to <30) to have participated in a behavioural programme or DiGA (OR = 2.73; CI 1.92–3.95; p < 0.001) and to be interested in such programmes (OR = 2.12; CI 1.76–2.57; p < 0.001) (also see online suppl. Fig. 5-1–5-3). Awareness of DiGAs differed slightly (OR = 1.28; CI 1.02–1.60; p = 0.03). Among participants with obesity, barriers to participating in a weight management programme or DiGA and reasons for not wanting to do so are displayed in online supplementary Figures 7-4 and 7-6. Obesity Medication Overall, 73.5% of all participants had previously heard of weight loss medications, and 59.8% believed medications to be effective for weight loss (Fig. 1). Most participants heard about obesity medications from the news (46.0%), social media (23.2%), or friends and family (17.6%) (online suppl. Table 8-2) and the mean rating of the level of feeling informed about weight loss medications was 1.72 (SD 0.83) on a scale from 1 to 4 (online suppl. Table 8-1). Overall, 9.3% of participants had talked to their GP about using medications for weight management and 6.2% of participants had experience using obesity medications. Most commonly used medications were Ozempic (40.2%) and Mounjaro (19.7%) (online suppl. Table 8-3). A majority of participants reported not to want treatment with medications (69.2%) and only 24.7% indicating an interest in using obesity medications (Fig. 2). Of those that reported being interested in using medications but have not yet done so (N = 510), most common reasons for that included not feeling sufficiently informed yet (39.0%), worries about side effects (34.3%), the medication being too expensive and/or not reimbursed by health insurance (26.1%), worries about long-term consequences (24.7%), feeling unsure if medications were the right fit for them (20.6%), doubting the long-term effectiveness of medications for weight loss (19.4%), and not knowing about medications before (15.3%) (online suppl. Fig. 8-1). Of those that reported not wanting to use medication for weight management (N = 1,428), most commonly selected reasons included being too worried about side effects (39.5%), believing that medications were the wrong approach for them (36.1%), not thinking medications were effective long term (31.5%), being too worried about long-term consequences (30.9%), not feeling they needed help with weight management urgently enough yet (23.6%), not wanting to take medication in general (19.5%), not actively trying to manage weight at the time (18.7%), and not feeling sufficiently informed (15.5%) (online suppl. Fig. 8-3). Participants with obesity (BMI ≥30) were more likely than those with overweight (BMI ≥25 to <30), to be aware of medication (OR = 1.41; CI 1.15–1.73; p < 0.001), have talked to their GP about medications (OR = 3.26; CI 2.33–4.62; p < 0.001), have taken medications for weight loss (OR = 2.84; CI 1.90–4.32; p < 0.001), and to be interested in treatment with medication (OR = 2.80; CI 2.26–3.48; p < 0.001) (also see online suppl. Fig. 5-1–5-3). Barriers to pharmacological treatment and reasons against its use among participants with obesity are presented in online supplementary Figures 8-2 and 8-4. Discussion In this representative cross-sectional survey of adults living with overweight and obesity in Germany, most participants had experience trying to manage their weight (85.5%), but these attempts were largely self-directed (75.1%), and the majority reported no weight loss maintenance (86.5%). Engagement with professional obesity care was low: fewer than half had discussed weight management with their GP (43.1%), and fewer than 10% had participated in a structured behavioural weight management programme (7.8%) or had used medications to support weight loss (6.2%). Interest in professional care varied across modalities, with the highest interest observed for behavioural programmes (39.1%). Across all forms of treatment, both interest and engagement were higher among participants with obesity (BMI ≥30 kg/m2) compared to those with overweight (BMI ≥25 kg/m2). Common barriers to the utilization of evidence-based care included lack of awareness, uncertainty about the right source of support, concerns about long-term effectiveness and side effects, discomfort discussing weight, and perceptions that assistance was not needed urgently enough yet. Despite high recognition of obesity as a disease [37], participants overwhelmingly relied on self-directed weight management attempts. This mirrors findings from the UK and other European countries, where professional support is only sought by 30–40% of individuals living with obesity [38, 39]. Similarly, a survey by Rigas et al. [40] found that 54% of respondents with obesity felt it was their own responsibility to manage their weight. Given that self-directed approaches are known to yield only modest and often temporary benefits – consistent with the high rates of weight regain reported in our sample – the predominance of self-management suggests that opportunities for professional obesity care are not being fully realized. The GP practice is thought to play a particularly important role in facilitating professional weight management support by acting as first point of contact and coordinator of care [11–14]. This potential has recently been acknowledged in Germany, where the federal joint committee approved the introduction of a regional-contract-based Disease Management Programme (DMP) for obesity in 2024 [41]. The DMP aims to provide guideline-based care, with GPs enrolling eligible participants, referring them to suitable programmes, and monitoring their care in regular follow-ups. However, in our findings, GP involvement in weight management remained limited. Although 43.1% of participants had talked to their GP about weight management, only a further half of them rated GP conversations as helpful. This may be explained by low referral rates to specific and reimbursed weight management services: most participants reported receiving general advice on diet and exercise, no specific recommendations, a warning, or a suggestion to try self-directed approaches, all without specific further action or intervention. This aligns with conclusions from a qualitative study in Germany by Wangler and Jansky [42], finding that while patients with obesity considered GPs to be central to treatment support, they were rarely offered anything beyond generalized advice, with limited referrals to specific programmes. A survey study of over 4,000 German GPs by the same authors found just over half of GPs indicated to have recommended specific offers and just over a third to have referred patients to specific services [43]. The authors further found that only 56% of participating GPs were aware of the national obesity treatment guidelines, even fewer reported to use them regularly, and many felt that a satisfactory overview of available services or referral options was lacking for their area [43]. Undeniably, low referral rates and GPs’ limited awareness of services reflect the scarcity of evidence-based treatment programmes available in Germany, both overall and within statutory health insurance, leaving GPs with little room for action [16]. DiGAs are currently the only universally reimbursed treatment option in Germany [16], and although we observed substantial interest in the use of DiGAs (39.1%) and previous literature indicates high acceptance [44], actual use (7.8%), awareness (19.6%) and GP-initiated prescriptions (4.5%) were rarely reported. Similar numbers were reported by Gemesi et al. [17], where only 28% of participants with obesity were aware of available DiGAs and only 3.3% had used them. This gap in DiGA uptake persists despite national utilization data indicating a steadily increased use since the first introduction of DiGAs in 2019, with obesity-focused applications most frequently used, reaching up to 234.5 thousand activation codes in total [45]. Nevertheless, low DiGA prescription rates were also found by Wangler and Jansky [43], where only 29% of surveyed GPs had prescribed specialized DiGA apps to patients with obesity. Dahlhausen et al. [46] further found that low prescription intentions among healthcare practitioners were largely driven by insufficient information along with uncertainties around their evidence base as well as technological and legal requirements. These barriers are consistent with participants’ limited awareness of DiGAs and reservations about their effectiveness, highlighting the need to improve information provision for both patients and healthcare practitioners to enhance treatment delivery. Previous studies have identified several further factors that contribute to suboptimal quality of care and may help explain low ratings on the perceived helpfulness of GP conversations. These include an incidental or late diagnosis of obesity, a lack of ongoing counselling and inconsistent goal setting within primary care, the receipt of contradictory information, short consultation times, physician knowledge and confidence in addressing obesity, insurance type, as well as persistent weight bias and stigma in healthcare settings [27, 40, 42, 47–51]. Given these challenges, some obesity patients have contested the suitability of the GP practice to deliver obesity care [27]. Similarly, in our study, 42.2% of participants indicated they did not want to talk to their GP about weight management and 14.7% would like to but have not done so yet. Our participants frequently reported insufficient urgency, doubts about the GPs role or competence, and discomfort raising the topic or fears that weight management would not be taken seriously. Similar delays in help seeking have been documented internationally; for example, an Australian survey found a mean delay of 8.9 years from participants first struggles with weight management to seeking healthcare support [40]. This hesitancy limits the provision of care and underscores the need to address patients’ concerns. Additionally, patient-level factors, such as socioeconomic status [52, 53] and age [54], may further impact the receipt of weight-related consultations and referrals, raising concerns about equitable access to care. Enhancing clarity on the GP’s role in weight management, providing GPs with training on the topic, strengthening their connections to cross-disciplinary specialist networks [43], or establishing multicentric obesity treatment hubs to complement primary care-based models [27] may improve care and reduce patient apprehensions. Addressing these barriers may also require increasing the awareness of obesity as a public health priority and ensuring that staff in primary care practices are trained and empowered to provide equitable, stigma-sensitive support. Pharmacological treatments represent a recent and promising development in obesity care, yet their integration into practice remains underexplored. While most participants were aware of and believed obesity medications to be effective, almost 70% were reluctant to use them. This is in line with Gemesi et al.’s [17] recent survey equally identifying high awareness, but low use and interest in obesity medications. We found most common barriers included concerns about side effects (39.5%), beliefs medication is the “wrong approach” (36.1%), long-term effectiveness (31.5%), and health consequences (30.9%). These findings align with another international survey in which German respondents reported particularly low satisfaction and high concerns about side effects [32] and with qualitative research highlighting additional apprehensions, including concerns about weight regain and long-term use, cost, and believing treatment would not work without lifestyle changes [55]. Beliefs that medication is the “wrong approach” may further reflect internalized weight stigma and societal narratives around “willpower” or taking “the easy way out” [55, 56], which also remains present in healthcare settings where only certain motivations for weight loss are perceived as valid and treatment may be offered selectively [57]. Clear communication, shared decision-making, and broader practitioner and public education on indications and realistic expectations may help reduce misconceptions and destigmatize obesity treatment. Strengths and Limitations Key strengths of this paper include the large sample size and the use of a quota-based sampling approach approximating the German adult population across key sociodemographic characteristics, allowing to gain a comprehensive understanding of the underexplored weight management landscape among individuals with overweight and obesity in Germany. However, although quotas were applied to enhance comparability with the general population, the use of panel-based sampling may introduce self-selection bias and limit full representativeness. Additionally, the self-reported nature of the survey needs to be taken into account when interpreting findings, which may be prone to both social desirability and recollection bias. As such, people may respond with more favourable answers on questions relating to their weight and health and may have biased memory in regards to their past weight management and healthcare seeking behaviour. Thus, findings from our study remain to be validated with more objective data, such as referral data from healthcare records. Additionally, access to and eligibility for treatment options may differ across participants and BMI groups as these are often subject to BMI-based criteria in clinical practice and reimbursement structures (e.g., DiGAs typically require BMI ≥30; pharmacotherapy BMI ≥27 with comorbidities or BMI ≥30). Consistent with this, we observed greater awareness, use, and interest in treatment options for participants with obesity. Finally, the exclusively quantitative collection of pre-specified items limits the depth of insights into concerns and barriers to treatment-seeking behaviour. More qualitative studies are needed to follow up on the barriers identified in this study, such as the reasons for not wishing to engage in GP conversations about weight loss, to gain a better understanding of patients’ needs and potential strategies for improvement. Conclusion Our findings highlight a substantial evidence-practice gap in German obesity care. While weight management attempts were common, they were largely self-directed, indicating underutilization of professional support. The role of GPs in weight management was contested, with just under half of consultations perceived as unhelpful. Awareness of structured behavioural programmes and DiGAs was low, though interest was considerable, suggesting potential for future uptake. Awareness of pharmacological treatments was higher, but interest remained low due to concerns about side effects and long-term use. Strengthening primary care as a coordinating hub (e.g., through targeted GP training, decision-support tools, connection to cross-disciplinary networks, and integration of referral pathways within the new DMP) could improve access to professional weight management support. System-wide transparency, expanded awareness campaigns for reimbursed options such as DiGAs, and timely reimbursement for effective pharmacotherapy and behavioural interventions are critical to reduce barriers and increase equitable access. Acknowledgment Data were collected by GIM (Gesellschaft für Marktforschung). Statement of Ethics Ethical approval for this study was obtained by the Ethics Committee II of Heidelberg University (“Ethik-Kommission II der Universität Heidelberg”) on the 29th of April 2025 (2025-517-AF 5). Written informed consent was obtained online by all participants. Conflict of Interest Statement L.K. applied for a grant with Oviva as collaborating party (outcome pending). All other authors report no conflicts of interest. Funding Sources This work was supported by the institutional start-up funds (“Berufungsmittel”) of F.S. at Heidelberg University. Author Contributions L.K.: conceptualization, methodology, formal analysis, visualization, and writing – original draft; H.Z.H.: methodology, visualization, and writing – original draft; H.H.: methodology and writing – review and editing; and F.F.S.: conceptualization, methodology, funding acquisition, supervision, and writing – review and editing.